After Atherectomy: Shockwave Medical Preps For Success
This article was originally published in Start Up
Executive Summary
An increasing proportion of patients are presenting to cath labs with calcified plaque, and emerging cardiovascular interventions are driving the demand for calcium debulking technologies that are more benign than conventional atherectomy or balloon angioplasty. Shockwave Medical’s novel platform for debulking calcified plaque in vessels is based on lithotripsy, the use of mechanical energy to fracture kidney stones; the start-up believes it has a technology that’s specific for calcium and benign to healthy tissue.
You may also be interested in...
Emerging PAD Devices Impress With New Trial Results, Funding
Two very different ways to treat peripheral arterial disease – lithotripsy combined with angioplasty and nitinol Tack implants – have demonstrated impressive six-month and one-year clinical results, respectively, and companies with these devices continue to attract funding.
PAD-Focused Medtechs Eye Golden Period In Growing Silver Market
Improving the patient’s QoL and preventing disease progression, and with it the threat of critical limb ischemia and amputation, dominate peripheral artery disease management, but emerging technologies and the aging population are set to boost a percutaneous transluminal angioplasty market that is already worth $730 million in the US alone.
The A-List: The Trend-Shaping Series A Financings Of 2014
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.